Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19

To clarify the effect of aspirin on mortality and viral duration in adults infected with respiratory syndrome coronavirus 2 (SARS-Cov-2). After propensity score-matched (PSM) case-control analyses 24 pairs of patients were enrolled and followed up for 2 months. Both 30-day and 60-day mortality in the aspirin group were significantly lower than that in the non-aspirin group (P = .021 and P = .030, respectively). The viral duration time between the 2 groups was not significantly different (P = .942). Among adults (with hypertension, cardiovascular diseases) infected with SARS-Cov-2, low-dose aspirin medication (100 mg/day) was associated with lower risk of mortality compared with non-aspirin users.

Automated summary

In a study involving adults infected with SARS-Cov-2, it was found that patients using low-dose aspirin (100 mg/day) had significantly lower 30-day and 60-day mortality rates compared to those not using aspirin, although there was no significant difference in viral duration between the two groups.